Form 4: Kymera Director Sells Shares After Option Exercise

Kymera Therapeutics Director Jeffrey W. Albers exercised stock options and subsequently sold 5,000 shares of common stock for a significant profit, as per a pre-arranged 10b5-1 trading plan.

Summary

• Director Jeffrey W. Albers of Kymera Therapeutics, Inc. engaged in transactions involving the company's common stock.
• On October 13, 2025, 5,000 stock options were exercised at a price of $10.34 per share.
• Immediately following the exercise, 5,000 shares of common stock were sold at a weighted average price of $59.1898 per share.
• The sale price ranged from $59.00 to $59.42 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Albers on September 20, 2024.
• Following these transactions, Mr. Albers beneficially owns 0 shares of common stock directly from these specific transactions.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction executed under a pre-arranged 10b5-1 plan. This type of transaction is generally considered neutral as it reflects personal financial planning rather than a direct signal about the company's operational performance or future prospects.

Positives

• Director Jeffrey W. Albers realized a substantial profit of approximately $244,249 from the exercise and sale of shares ($59.1898 $10.34 = $48.8498 profit per share * 5,000 shares).
• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planned and orderly insider trading, which can mitigate concerns about opportunistic selling.

Negatives

• The sale of shares by a director, even if pre-planned, could be perceived by some investors as a lack of confidence, although the 10b5-1 plan context typically lessens this interpretation.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing, a routine insider transaction report, does not provide information relevant to broader industry trends or competitive landscape analysis.

Stakeholder Impact

• Shareholders: May observe insider selling, but the context of a Rule 10b5-1 plan typically suggests personal financial management rather than a negative signal about the company's fundamentals. The director's beneficial ownership of common stock from these specific transactions is now 0.

Key Dates

Recommendation

The filing details a routine insider transaction executed under a pre-arranged 10b5-1 plan, which is a common practice for corporate insiders for personal financial management. It does not provide new operational or financial information about Kymera Therapeutics, Inc. that would alter the fundamental investment thesis. Therefore, a 'hold' recommendation is appropriate as this event alone does not signal a significant positive or negative shift in the company's prospects.

Keywords

Kymera Therapeutics, KYMR, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Jeffrey W. Albers, 10b5-1 Plan